Id: acc1909
Group: 2sens
Protein: HSP27
Gene Symbol: HSPB1
Protein Id: P04792
Protein Name: HSPB1_HUMAN
PTM: phosphorylation
Site: Ser15
Site Sequence: VPFSLLRGPSWDPFRDWYPHS
Disease Category: Cancer
Disease: Lung Cancer
Disease Subtype: LUSC
Disease Cellline: SK-MES-1?
Disease Info:
Drug: dioscin
Drug Info: "Dioscin is a natural steroidal saponin with demonstrated anti-inflammatory, immunomodulatory, and antitumor effects, particularly in inhibiting the growth of various cancer cells such as melanoma, leukemia, and breast cancer cells."
Effect: modulate
Effect Info: "Dioxin causes the accumulation of reactive oxygen species (ROS) in pulmonary squamous cell carcinoma (SCC) cells, which in turn triggers the phosphorylation of heat shock protein 27 (HSP27), ultimately leading to cell apoptosis."
Note:
Score: 4.0
Pubmed(PMID): 33061803
Sentence Index:
Sentence:

Sequence & Structure:

MTERRVPFSLLRGPSWDPFRDWYPHSRLFDQAFGLPRLPEEWSQWLGGSSWPGYVRPLPPAAIESPAVAAPAYSRALSRQLSSGVSEIRHTADRWRVSLDVNHFAPDELTVKTKDGVVEITGKHEERQDEHGYISRCFTRKYTLPPGVDPTQVSSSLSPEGTLTVEAPMPKLATQSNEITIPVTFESRAQLGGPEAAKSDETAAK

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 2 Unknown status squamous cell lung carcinoma ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 2 Completed pancreatic carcinoma ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 2 Completed non-small cell lung carcinoma ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 2 Completed prostate cancer ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 2 Terminated prostate cancer ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 1 Completed neoplasm ClinicalTrials
HSPB1 APATORSEN Heat shock protein beta-1 (HSP27) mRNA antisense inhibitor 1 Unknown status urinary bladder cancer ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
HSPB1-Ser15
Cancer Intensity
BRCA 1.131
COAD 0.266
HGSC 0.504
ccRCC -1.22
GBM 0.362
HNSC 0.495
LUAD 0.979
LUSC 0.929
non_ccRCC -1.325
PDAC -1.655
UCEC -0.466

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 15 N Dilated cardiomyopathy Phosphorylation 34477462
S 15 P Pancreatic cancer/carcinoma/adenocarcinoma Phosphorylation 22012255

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A549 Dactolisib 7.0386 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A549 Dactolisib 6.1671 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A549 PD325901 8.1361 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A549 Staursporin 7.7495 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR BT-474 Lapatinib 6.5032 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR HeLa CUDC101 4.5058 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR HeLa Curcumin 4.2586 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR HeLa Curcumin 4.25 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR RPMI8226 BTZ 8.5138 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR RPMI8226 BTZ 7.8 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR RPMI8226 BTZ 7.4001 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR RPMI8226 BTZ 7.0921 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR RPMI8226 BTZ 6.9555 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR RPMI8226 BTZ 6.389 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR RPMI8226 BTZ 7.4801 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR RPMI8226 BTZ 7.3997 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR RPMI8226 BTZ 6.7534 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR RPMI8226 BTZ 6.5452 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR RPMI8226 BTZ 7.7445 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR RPMI8226 BTZ 7.7014 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR RPMI8226 BTZ 7.6158 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR RPMI8226 BTZ 7.0533 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR RPMI8226 BTZ 7.7054 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR RPMI8226 BTZ 7.6617 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR RPMI8226 BTZ 7.5674 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR RPMI8226 BTZ 7.3704 up
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A431 Afatinib 5.7204 down
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A431 Afatinib 6.5325 down
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A431 Afatinib 6.0041 down
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A431 Afatinib 6.5034 down
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A431 Afatinib 5.4989 down
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A431 Dasatinib 6.1463 down
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A431 Dasatinib 6.2189 down
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A431 Dasatinib 5.8113 down
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A431 Dasatinib 5.4376 down
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A549 Dasatinib 6.564 down
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A549 Dasatinib 5.683 down
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR K562 Dasatinib 7.0751 down
P04792 HSPB1 P Ser15 GPS(ph)WDPFR K562 Dasatinib 6.6265 down
P04792 HSPB1 P Ser15 GPS(ph)WDPFR PC-9 Lapatinib 6.5724 down
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A431 Afatinib 8.3291 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A431 Afatinib 6.5223 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A431 Afatinib 5.4981 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A431 Dasatinib 8.6231 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A431 Dasatinib 6.1505 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A431 Dasatinib 5.7707 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A431 Dasatinib 5.7395 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A431 Dasatinib 5.6263 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A431 Gefitinib 9.2446 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A431 Gefitinib 4.001 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A431 Gefitinib 6.9723 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A431 Gefitinib 6.9156 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A431 Gefitinib 7.4712 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A431 Gefitinib 6.9889 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A431 Imatinib 6.7762 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A431 Imatinib 3.4319 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A459 MK2206 8.5251 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A459 MK2206 8.3863 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A459 MK2206 5.7602 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A459 Selumetinib 5.2463 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A459 Selumetinib 6.3664 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A459 SelumetinibMK2206-3to1 8.4613 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A549 AZD8055 7.8265 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A549 AZD8055 7.4392 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A549 Dasatinib 6.8512 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A549 Dasatinib 6.2356 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A549 MK2206 5.7652 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A549 MK2206 5.2513 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A549 Nintedanib 10.6855 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A549 PD325901 8.1353 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A549 PD325901 7.0465 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A549 PD325901 6.587 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A549 Pictilisib 7.7413 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A549 Refametinib 7.5088 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A549 Refametinib 7.2842 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A549 Staursporin 7.8365 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR A549 Tideglusib 10.9418 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR A549 Tideglusib 8.7447 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR ARH-77 Rituximab -1.6613 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR ARH-77 Rituximab -3.2566 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR ARH-77 Rituximab -3.4003 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR ARH-77 Rituximab -4.2413 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR ARH-77 Rituximab -3.4711 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR ARH-77 Rituximab -3.296 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR ARH-77 Rituximab -3.7576 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR ARH-77 Rituximab -3.4781 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR ARH-77 Rituximab -1.2107 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR ARH-77 Rituximab -3.1815 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR ARH-77 Rituximab -3.7376 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR BT-474 Lapatinib 6.7577 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR BT-474 Pertuzumab -3.7582 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR BT-474 Pertuzumab -4.2656 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR BT-474 Trastuzumab -2.2243 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR BT-474 Trastuzumab -2.7376 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR HeLa A485 5.6142 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR HeLa A486 7.7147 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR HeLa A486 3.1907 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR HeLa Romidepsin 12.1532 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR HeLa Romidepsin 12.0383 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR K562 Cytarabine 6.7877 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR K562 Cytarabine 6.3666 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR K562 Dasatinib 9.1492 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR K562 Dasatinib 9.1344 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR K562 Dasatinib 9.0807 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR K562 Dasatinib 9.0772 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR K562 Dasatinib 10.0727 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR K562 Dasatinib 10.0126 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR K562 Dasatinib 9.52 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR K562 Dasatinib 9.4952 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR K562 Dasatinib 4.5651 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR K562 Dasatinib 4.4624 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR K562 Dasatinib 4 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR K562 Dasatinib 4 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR K562 Imatinib 5.5879 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR K562 Imatinib 5.4147 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR K562 Paclitaxel 5.1484 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR KYSE-520 SHP099 5.4432 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR KYSE-520 SHP099 4.0277 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR MDA-MB-175 Lapatinib 7.0175 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR MDA-MB-175 Pertuzumab -1.23 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR MDA-MB-175 Pertuzumab -4.2682 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR MDA-MB-175 Trastuzumab -0.7219 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR MDA-MB-175 Trastuzumab -2.2413 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR PC-9 AZD4547 5.2512 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR PC-9 AZD4547 7.5602 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR PC-9 GeftinibAZD4547-1to80 9.4301 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR PC-9 LapatinibAZD4547 10.5242 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR RPMI8226 BTZ 6.4557 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR RPMI8226 BTZ 6.4312 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR SK-BR-3 Lapatinib 7.252 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR SK-BR-3 Lapatinib 6.1733 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR SK-BR-3 Pertuzumab 0.9056 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR SK-BR-3 Pertuzumab -0.9196 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFR SK-BR-3 Trastuzumab -2.0088 -
P04792 HSPB1 P Ser15 GPS(ph)WDPFRDWYPHSR SK-BR-3 Trastuzumab -2.9615 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: